Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Procter & Gamble HealthBOM:500126 -1.99%86 Shareholder Yield % is 2.32% as of Mar. 2026, which is 137% above its 10-year median of 0.98. GuruFocus rates BOM:500126 with a GF Score™ of 86/100 and a GF Value™ of ₹6,112.54 (Fairly Valued). The stock has 6 warning signs investors should review. Among 971 Drug Manufacturers companies, Procter & Gamble Health ranks better than 66.94% on this metric.
Shareholder Yield % is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. It is a measure of shareholder return.
As of today, Procter & Gamble Health's Shareholder Yield % was 2.32%.
Procter & Gamble Health (BOM:500126) Shareholder Yield % Explanation
Shareholder Yield % is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. The term was coined by William W. Priest of Epoch Investment Partners in a paper in 2005 entitled The Case for Shareholder Yield as a Dominant Driver of Future Equity Returns. William Priest indicated that "shareholder yield is a term that we came up with to reflect the various ways dividends can be paid to owners of a business in a publicly-traded company."
Dividend Yield % shows how much a company pays out in dividends each year relative to its stock price, which is most obvious form of shareholder return.
Buyback Yield % is the net repurchase of shares outstanding over the market capital of the company. Shares repurchases also increase shareholder value by returning the money back to shareholders.
Net Debt Paydown Yield % is the change in average of four quarters of company's total debt over a company's market cap. Assuming the total value of a company remains that same, shareholder value is increased as debt is reduced.
Procter & Gamble Health Shareholder Yield % Related Terms
Procter & Gamble Health Shareholder Yield % Historical Data
* Premium members only.
The historical data trend for Procter & Gamble Health's Shareholder Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Procter & Gamble Health's Shareholder Yield %, along with its competitors' market caps and Shareholder Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Procter & Gamble Health Shareholder Yield % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Procter & Gamble Health's Shareholder Yield % distribution charts can be found below:
* The bar in red indicates where Procter & Gamble Health's Shareholder Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* All the data are calculated by TTM values. Note that if a companies is traded in several exchanges, then we calculate the company level data for Shareholder Yield % using the primary share class stock data. The calculation result in definition page is for demonstration purpose only, and it's showing the share class level data. Therefore, the numbers in the calculation may differ from elsewhere if the stock is not a primary share.
Procter & Gamble Health (BOM:500126) has a Shareholder Yield % of 2.32% as of Mar. 2026. Shareholder Yield is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. View historical data on Procter & Gamble Health and its competitors. This is 137% above median its historical median of 0.98. Over the past decade, Procter & Gamble Health's Shareholder Yield % has ranged from 0.41 to 3.24. According to the industry distribution chart, Procter & Gamble Health ranks #321 out of 971 companies in the Drug Manufacturers industry, placing it in the top 33.1%.
Is Procter & Gamble Health's Shareholder Yield % too high?
Procter & Gamble Health's current Shareholder Yield % of 2.32% is 137% above median its 10-year median of 0.98. Over the past 10 years, this metric has ranged from a low of 0.41 to a high of 3.24. The Drug Manufacturers industry median Shareholder Yield % is 0.30. Procter & Gamble Health's value of 2.32% is 673.3% above this industry median. Based on the distribution chart, Procter & Gamble Health ranks #321 out of 971 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Procter & Gamble Health has a GF Score™ of 86/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Procter & Gamble Health's Shareholder Yield % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Procter & Gamble Health ranks #321 out of 971 companies for Shareholder Yield %. This puts Procter & Gamble Health in the upper half of its industry. The industry median Shareholder Yield % is 0.30. Procter & Gamble Health's value of 2.32% is 673.3% above this benchmark. Historically, Procter & Gamble Health's own Shareholder Yield % has ranged from 0.41 to 3.24 over the past decade. While the company's 10-year median is 0.98 vs. the industry median of 0.30, Procter & Gamble Health has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Shareholder Yield % for a Drug Manufacturers company?
The median Shareholder Yield % among Drug Manufacturers companies is 0.30, based on 971 companies in the industry. Companies in the top quartile (top 25%) have a Shareholder Yield % significantly above this median, while those in the bottom quartile fall well below. However, Shareholder Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Procter & Gamble Health's current Shareholder Yield % of 2.32% is 673.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Shareholder Yield % mean?
A high Shareholder Yield % can signal that a stock is expensive relative to its fundamentals. Shareholder Yield is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. View historical data on Procter & Gamble Health and its competitors. For the Drug Manufacturers industry, the median Shareholder Yield % is 0.30 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Procter & Gamble Health's current Shareholder Yield % is 2.32%, which is 137% above median its own 10-year median of 0.98. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Procter & Gamble Health stock overvalued right now?
Based on GuruFocus' analysis, Procter & Gamble Health (BOM:500126) is currently considered Fairly Valued. The stock's GF Value™ is ₹6,112.54, compared to a current price of ₹6,490.60 — trading 6.2% above its estimated fair value. The current Shareholder Yield % is 2.32%, which is 137% above median its 10-year median of 0.98 and 673.3% above the Drug Manufacturers industry median of 0.30. Procter & Gamble Health's overall GF Score™ is 86/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Shareholder Yield % calculated?
Shareholder Yield % is calculated from a company's financial statements. For Procter & Gamble Health (BOM:500126), the current Shareholder Yield % is 2.32% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Procter & Gamble Health (BOM:500126) Overvalued in 2026?
Based on GuruFocus' analysis, Procter & Gamble Health stock appears to be overvalued.
The current stock price of ₹6,490.60 is trading 6.2% above its estimated GF Value™ of ₹6,112.54.
GuruFocus considers Procter & Gamble Health to be Fairly Valued.
Key valuation signals for BOM:500126:
Shareholder Yield %: 2.32% (137% above median its 10-year median of 0.98)
GF Value™: ₹6,112.54 vs. price of ₹6,490.60 (6.2% above fair value)
Industry Position: 673.3% above the Drug Manufacturers median (#321 of 971)
No single metric tells the full story. See the BOM:500126 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Procter & Gamble Health Ltd is an India based pharmaceutical company engaged in manufacturing and selling of healthcare products, viz., vitamins, minerals and supplements. Patients are end consumers of the products. The Company's distribution channels (direct & indirect), inter alia, include distributors, health care professionals, pharmacies and chemists. Cosome, Evion, Neurobion, Nasivion, Polybion, Livogen and Seven Seas are some of the brands of the company. The geographical segments include sales in India and exports.
86GF Score
Get the complete analysis for BOM:500126
Shareholder Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:500126 has been successfully added to your 
